Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients

In conclusion, PTLD patients in CR after rituximab have an excellent long-term outcome. These results not o nly apply in the clinical trial setting but are also reproducible in the real world. However, those patients who do not respond represent an unmet clinical need and should be included in prospective clinical trials.
Source: Annals of Hematology - Category: Hematology Source Type: research